Exact Sciences Partners with Carlos Ponce to Boost Colorectal Cancer Awareness in the Hispanic Community

Merck Receives Positive CHMP Opinion for KEYTRUDA® in Combination Therapy for First-Line Treatment of Non-Epithelioid Mesothelioma

Australia Launches Genomics Australia to Lead Advances in Genomic Medicine

Sidra Medicine Unveils Masterclasses Ahead of PMFG 2024 Summit

FDA Approves Revuforj® as First Menin Inhibitor for Acute Leukemia with KMT2A Translocation

CHMP Recommends Approval of Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Home
/
update
/
details

Lucid Diagnostics Secures Key Patent Allowance for EsoGuard Esophageal DNA Test

NextEdge Admin

16 Oct 2024

2 min 28 sec

next-generation sequencing,esophageal cancer

Lucid Diagnostics , a commercial-stage cancer prevention diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a key patent application. The patent covers Lucid’s proprietary method using methylation of the cyclin-A1 (CCNA1) gene to detect esophageal precancer and cancer, a core feature of the EsoGuard® Esophageal DNA Test.

“This patent enhances our already strong intellectual property portfolio and provides robust protection for the CCNA1 methylation assay, a critical component of the EsoGuard test,” said Lishan Aklog, M.D., Lucid’s Chairman and CEO. “It validates our strategic focus on the laboratory methods of the assay, a path we will continue to pursue for other components.”

The EsoGuard test applies next-generation sequencing (NGS) technology to assess DNA methylation at 31 sites on two genes—vimentin (VIM) and cyclin-A1 (CCNA1). While VIM methylation had been linked to gastrointestinal neoplasias, the association between CCNA1 methylation and esophageal neoplasia is novel and demonstrates higher specificity for conditions like Barrett’s Esophagus (BE) and esophageal adenocarcinoma.

The technology behind EsoGuard and the EsoCheck® Esophageal Cell Collection Device was developed by faculty from Case Western Reserve University (CWRU) with support from the National Institutes of Health (NIH). Lucid holds exclusive global licensing rights to commercialize the technology, which was transferred from research to market through close collaboration with CWRU.

Lucid focuses on patients with chronic GERD, aiming to prevent esophageal cancer through early detection using noninvasive tools like EsoGuard and EsoCheck.